Clinical Trial Update: BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Brentuximab Vedotin as pre-ASCT induction therapy in relapsed/refractory Hodgkin's lymphoma patients who did not respond to IGEV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Relapsed/Refractory Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED